CircHIPK3 Promotes Gemcitabine (GEM) Resistance in Pancreatic Cancer Cells by Sponging miR-330-5p and Targets RASSF1

BACKGROUND: Pancreatic cancer is one of the most common malignant diseases in the world. Gemcitabine chemotherapy remains the most important clinical treatment. However, research found that pancreatic cancer cells have chemoresistance to gemcitabine and the effect is not satisfactory. Therefore, it...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yunfei, Xia, Li, Dong, Luo, Wang, Jiale, Xiao, Qiangsheng, Yu, Xiao, Zhu, Hongwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023912/
https://www.ncbi.nlm.nih.gov/pubmed/32104074
http://dx.doi.org/10.2147/CMAR.S239326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023912/
https://www.ncbi.nlm.nih.gov/pubmed/32104074
http://dx.doi.org/10.2147/CMAR.S239326

Ejemplares similares